IP Library Granted Patent US 7,605,177
Granted Patent B2
US 7,605,177 · App. 11/314,424 · Granted Oct 20, 2009

Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,605,177
App. No.
11/314,424
Granted
Oct 20, 2009
Kind
B2
Abstract

This invention provides analogs and peptidomimetics of glycyl-L-prolyl-L-glutamic acid (GPE). In particular, this invention relates to GPE analogs and peptidomimetics that are anti-apoptotic, anti-necrotic and have neuroprotective effects. These agents are useful in treating neurodegeneration and behavioural disorders caused by toxins, traumatic brain injury and autoimmune disorders of the brain, such as multiple sclerosis and in reducing seizures.

Claims (13)

1. A method of treating an animal having a neurological injury caused by traumatic brain injury, comprising administration to an animal in need thereof a therapeutically effective amount of glycyl-L-2-methyl prolyl-L-glutamic acid (G-2MePE) to provide relief from a symptom of said traumatic brain injury.

2. The method of claim 1 where said traumatic brain injury causes stroke.

3. The method of claim 1 where said injury is penetrating brain injury.

4. The method of claim 1 where said traumatic brain injury causes hypoxia of the brain.

5. The method of claim 1 where said traumatic brain injury causes ischemia of the brain.

6. The method of claim 1 where at least one other anti-apoptotic or neuroprotective agent is administered.

7. The method of claim 1 , where said traumatic brain injury is characterized by loss of neural cells from said animal's brain.

8. The method of claim 1 , where said symptom of traumatic brain injury is a seizure.

9. The method of claim 1 , where said symptom of traumatic brain injury is a motor disorder.

10. The method of claim 9 , where said motor disorder is a disorder of gait.

11. The method of claim 1 , where said traumatic brain injury causes injury to cortical cells, striatal cells, or cerebellar cells.

12. The method of claim 1 , where said condition or injury is characterized by an increase astrocytic or microglial cell activation within the said animal's brain.

13. A method for reducing a seizure induced by traumatic brain injury comprising administering to an animal in need thereof a pharmacologically effective amount of G-2MePE.

Assignments (2)
CHANGE OF ADDRESS Recorded Jan 21, 2014
From: NEUREN PHARMACEUTICALS LIMITED
To: NEUREN PHARMACEUTICALS LIMITED
Reel/Frame 032111/0850 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2006
From: GLUCKMAN, PETER DAVID; THOMAS, GREGORY BRIAN; GUAN, JIAN; DRAGUNOW, MICHAEL; ANAND, ASHMIT; SIEG, FRANK; BRIMBLE, MARGARET ANNE
To: NEUREN PHARMACEUTICALS LIMITED
Reel/Frame 017942/0826 →